May 10, 2018 / 11:17 AM / 6 months ago

BRIEF-Karyopharm Therapeutics Reports Q1 Loss Per Share Of $0.78

May 10 (Reuters) - Karyopharm Therapeutics Inc:

* KARYOPHARM REPORTS FIRST QUARTER 2018 FINANCIAL RESULTS AND HIGHLIGHTS RECENT PROGRESS

* Q1 LOSS PER SHARE $0.78

* Q1 EARNINGS PER SHARE VIEW $-0.62 -- THOMSON REUTERS I/B/E/S

* PLANS TO SUBMIT NDA REQUESTING ACCELERATED APPROVAL FOR SELINEXOR IN PENTA-REFRACTORY MYELOMA DURING SECOND HALF OF 2018

* KARYOPHARM THERAPEUTICS - ORAL SELINEXOR ACHIEVES 25.4% ORR AND MEDIAN DURATION OF RESPONSE OF 4.4 MONTHS IN PATIENTS WITH PENTA-REFRACTORY MYELOMA Source text for Eikon: Further company coverage:

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below